M42

Ashish Koshy is the Chief Executive Officer of G42 Healthcare. Entrepreneurial and solutions driven, he is a business leader who specialises in converting challenges into strong business propositions. A global leader in transformation and innovation, Ashish has extensive experience across industries – ranging from banking to telecom and healthcare, driving Big Data and AI strategies across large international corporations. As CEO of G42 Healthcare, Ashish has been at the helm of developing AI-powered solutions for current and future challenges. He has built on public private partnerships and collaborated with government and private entities, such as the UAE Ministry of Health and Prevention (MoHAP), Department of Health – Abu Dhabi (DoH), as well as pharma companies, tech entities and academic institutions in the UAE and beyond to develop solutions that futureproof the health of nations. Ashish leads a multifaceted, growing organization with disruptive next generation solutions in diagnostics, digital health, therapeutics, and advanced Omics.

Dr. Fahed Al Marzooqi is the Chief Operating Officer of G42 Healthcare. In his current capacity, he leads the entire business operations. Dr. Fahed has over 15 years’ experience with large and diverse organizations. Prior to joining G42 Healthcare, he was the Chief Administrative Officer at Cleveland Clinic Abu Dhabi, where he was an integral part of multiple high-impact strategic programs for the hospital. Dr. Fahed led a multitude of business critical assignments with varying degrees of complexity and taken on progressive responsibilities to deliver strategic healthcare projects throughout his tenure. Dr. Fahed graduated with a Bachelor of Science in Mathematics and a Doctorate in Medicine from Dalhousie University in Canada. This was followed by a five-year residency program in anesthesiology at the University of British Columbia in Vancouver.

Dr. Sally Mahmoud is the Lab Director and Clinical Pathologist at Biogenix Labs, a G42 Healthcare company, built to address the need for population-scale detection and diagnosis of various infections. At Biogenix Labs, Dr. Sally leads a team of over 150 pathologists, technologists, biomedical engineers, and administrative staff, working to achieve excellence in clinical diagnostics as well as research on diagnostic methods and latest medical technologies. Dr. Sally led the sample testing for the #4Humanity trials – the world’s first Phase-III clinical trials for inactivated vaccine against COVID-19. As an expert in the clinical diagnostic space, she has published several papers in leading medical journals. Dr. Sally is also a visiting professor at Khwarizmi University.